- Home
- HON vs GILD Comparison
HON vs GILD Comparison
Compare HON & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HON
- GILD
- Stock Information
- Founded
- HON 1885
- GILD 1987
- Country
- HON United States
- GILD United States
- Employees
- HON N/A
- GILD N/A
- Industry
- HON Aerospace
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HON Industrials
- GILD Health Care
- Exchange
- HON Nasdaq
- GILD Nasdaq
- Market Cap
- HON 132.9B
- GILD 145.4B
- IPO Year
- HON N/A
- GILD 1992
- Fundamental
- Price
- HON $203.25
- GILD $117.92
- Analyst Decision
- HON Buy
- GILD Buy
- Analyst Count
- HON 14
- GILD 23
- Target Price
- HON $249.23
- GILD $116.82
- AVG Volume (30 Days)
- HON 4.7M
- GILD 7.7M
- Earning Date
- HON 10-23-2025
- GILD 10-30-2025
- Dividend Yield
- HON 2.23%
- GILD 2.68%
- EPS Growth
- HON 0.22
- GILD 496.80
- EPS
- HON 8.79
- GILD 5.01
- Revenue
- HON $39,990,000,000.00
- GILD $28,863,000,000.00
- Revenue This Year
- HON $7.54
- GILD $2.08
- Revenue Next Year
- HON $4.17
- GILD $3.96
- P/E Ratio
- HON $23.12
- GILD $23.52
- Revenue Growth
- HON 7.11
- GILD 3.81
- 52 Week Low
- HON $179.36
- GILD $85.60
- 52 Week High
- HON $242.77
- GILD $121.83
- Technical
- Relative Strength Index (RSI)
- HON 39.40
- GILD 60.07
- Support Level
- HON $200.61
- GILD $115.80
- Resistance Level
- HON $209.41
- GILD $119.33
- Average True Range (ATR)
- HON 3.92
- GILD 3.07
- MACD
- HON -0.20
- GILD 0.61
- Stochastic Oscillator
- HON 21.31
- GILD 72.16
About HON Honeywell International Inc.
Honeywell traces its roots to 1885 with Albert Butz's firm, Butz Thermo-Electric Regulator, which produced a predecessor to the modern thermostat. Other inventions by Honeywell include biodegradable detergent and autopilot. Today, Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. It operates through four business segments: aerospace technologies (37% of 2023 company revenue), industrial automation (29%), energy and sustainability solutions (17%), and building automation (17%). Recently, Honeywell has made several portfolio changes to focus on fewer end markets and align with a set of secular growth trends. The firm is working diligently to expand its installed base, deriving around 30% of its revenue from recurring aftermarket services.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).